New drug ARO-HSD tested for fatty liver disease – early results promising?
NCT ID NCT04202354
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tested a new drug, ARO-HSD, in 50 healthy people and patients with NASH, a serious fatty liver disease. The main goal was to see if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and dosing, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland Clinical Studies
Grafton, Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.